ADA/KDIGO 2022 - metformin in CKD
- Product / population
- Adults with type 2 diabetes and CKD; 2022 joint consensus, not asserted to be the latest 2026 guideline.
- Renal measure
- Indexed eGFR, mL/min/1.73 m2.
- Source revision
- 2022 ADA/KDIGO consensus, Diabetes Care 45:3075-3090
- Retrieved
- 2026-09-07 (not the revision date)
Renal dosing, restrictions and evidence limits
The consensus supports metformin in selected patients with type 2 diabetes and CKD at eGFR at least 30 mL/min/1.73 m2. Reduce to 1,000 mg daily at eGFR 30-44; consider reduction at 45-59 with high hypoperfusion or hypoxemia risk. Monitor eGFR every 3-6 months once below 60. A sick-day plan that holds metformin during acute illness may reduce lactic-acidosis risk, especially when AKI reduces clearance. The U.S. label separately discourages initiation at eGFR 30-45; distinguish a new start from continuation.
